[ad_1]
ImCheck published a seminal paper on Cell Report Clarify HOh Casein A kindActivate Vγ9Vδ2 T cells Feffect A kindobtain Tonhumor Cthey
- The first published study shows the role and sequential interaction of casein subtypes in inducing the cytotoxic response of human γ9δ2 T cells
- The results support the potential of therapeutic antibodies to bind to casein, which is an effective mechanism for targeted immune response against tumor cells
- Research shows ImCheck’s scientific leadership in regulating γδ T cells through casein superfamily immunomodulators
Marseille, France, July 13, 2021 —— ImCheck therapy Today announced the publication of pre-clinical data in a peer-reviewed journal, clarifying the basic role of casein (BTN) in activating V γ 9 V δ 2 (Vγ9Vδ2) T cells, leading to anti-tumor immune responses, Cell Report. The publication is titled “BTN2A1, an immune checkpoint against Vγ9Vδ2 T cell cytotoxicity Fight against malignant CtheySummarizing the discovery of interactions between specific BTN subtypes that effectively activate Vγ9Vδ2 T cells, Vγ9Vδ2 T cells are an important subset of cytotoxic γδ T cells. In addition, this publication shows that anti-BTN2A1 specific antibodies can inhibit cytotoxicity. Functional Vγ9Vδ2 T cells. This article was written in collaboration with the laboratory of ImCheck scientist and Professor Daniel Olive, professor and director of immunology.
The full story on Benzinga.com
[ad_2]
Source link
